Novo Nordisk to Unveil Semaglutide Data for Liver Disease Crisis

Novo Nordisk Unveils Semaglutide MASH Data at EASL 2026

Novo Nordisk is presenting new data at the EASL Congress 2026, highlighting semaglutide's role in addressing Metabolic Dysfunction-associated Steatohepatitis (MASH). The data from the ESSENCE Phase 3 program confirm semaglutide 2.4 mg's favorable hepatic safety profile and its benefits across diverse patient populations, including women in menopause and Japanese MASH patients. This aims to tackle MASH, a progressive liver disease affecting 250 million globally, which is largely undiagnosed and undertreated, with historically limited treatment options. The company's commitment is to ensure timely, evidence-based care for all MASH patients.

• The ESSENCE Liver Safety analysis demonstrated a favorable hepatic safety profile for semaglutide 2.4 mg, providing critical reassurance for hepatologists and treating physicians. This is particularly important for MASH patients who have inherently vulnerable liver function, making treatment safety paramount. Semaglutide is highlighted as the only GLP-1 RA clinically proven to renew liver health in this population.
• New subgroup analyses from the ESSENCE trial show semaglutide's efficacy extends to specific, often underserved patient groups. This includes women in menopause, where hormonal changes accelerate liver disease, and Japanese MASH populations, who exhibit unique metabolic and genetic risk profiles. These findings underscore the drug's potential for broad applicability and equitable access globally.
• The data presentation aims to bring a long-overdue spotlight on MASH, a progressive and potentially fatal liver disease affecting an estimated 250 million people worldwide. Despite its staggering prevalence, nearly 90% of cases remain undiagnosed and untreated, with patients historically lacking approved pharmacological treatments. Novo Nordisk's efforts seek to move closer to early detection and effective, evidence-based care.

The Critical Unmet Needs in MASH Treatment

Current MASH treatment faces significant challenges despite recent therapeutic advances. The complex, multifactorial nature of the disease has historically made regulatory approval difficult, with therapeutic development previously considered a "graveyard" due to numerous failed pharmacotherapies. While resmetirom recently received FDA approval, substantial gaps remain in treatment options and long-term efficacy data.

• Limited approved therapeutic options: No pharmacotherapies for MASLD are currently approved in Japan, and despite extensive research over the past decade, only one drug (resmetirom) has received FDA approval under accelerated pathways in the United States

• Uncertain long-term efficacy and safety: Much about resmetirom's long-term efficacy and safety remains undetermined, with ongoing challenges including durability, accessibility, and adverse effects such as gastrointestinal reactions

• Regulatory approval complexity: Achieving regulatory approval continues to be rigorous due to the complex nature of MASH, varying clinical outcomes used to assess treatment efficacy, and limitations of current surrogate histological endpoints

• Inadequate surrogate endpoint validation: Ongoing studies must define whether surrogate endpoints translate into decreased liver-related and all-cause morbidity and mortality in patients at risk for adverse clinical outcomes attributable to MASH

• Gastrointestinal tolerability issues: Both FDA-approved anti-obesity agents like GLP-1 receptor agonists and resmetirom are associated with higher rates of gastrointestinal adverse events, limiting their long-term utility and patient adherence

• Incomplete understanding of disease pathogenesis: The multifactorial nature of MASH pathogenesis necessitates continuing evaluation of alternative therapeutic options, as no single treatment has demonstrated universal efficacy

• Diagnostic and monitoring limitations: Future efforts must address non-invasive diagnostics alongside safety and long-term efficacy concerns to advance MASH management

• Clinical trial design inadequacies: Previous studies have been limited by small sample sizes, short durations, and inadequacies in clinical trial design, requiring further validation through large prospective studies

Semaglutide's Favorable Hepatic Safety Profile in ESSENCE

Recent clinical studies have demonstrated significant progress in MASH therapeutic development, with multiple drug classes showing promising results across different mechanisms of action. A comprehensive meta-analysis of GLP-1 receptor agonists examined seven randomized controlled trials involving 1,800 patients with baseline F2-F3 fibrosis stage over a mean follow-up of 136.8 weeks. The analysis revealed that GLP-1 receptor agonists achieved superior histological resolution of MASH without worsening fibrosis compared to placebo (risk ratio 2.96; 95% CI 1.70-5.15, p <0.001) and demonstrated improvement of fibrosis without worsening MASH (risk ratio 1.59; 95% CI 1.32-1.90, p <0.001). Additionally, these agents significantly improved aminotransferases, MRI-proton density fat fraction, HbA1c, serum lipids, blood pressure, and anthropometric parameters.

The MAESTRO-NASH trial, a randomized, double-blind, placebo-controlled phase 3 study, evaluated resmetirom, a selective thyroid hormone receptor β agonist, over 54 months in patients with MASH. The study successfully achieved its primary endpoints of MASH resolution without worsening of fibrosis and ≥1-stage improvement in fibrosis without worsening of MASH at 52 weeks. Notably, resmetirom-treated patients (100 mg) with weight loss ≥5% demonstrated higher rates of MASH resolution (56.6% vs. 33.8%) and fibrosis improvement (40.6% vs. 31.5%) compared to those with <5% weight loss. The efficacy remained consistent regardless of background SGLT2 inhibitor or GLP-1 receptor agonist treatment, though weight loss enhanced therapeutic outcomes.

Safety profiles across these studies showed generally acceptable tolerability with specific adverse event patterns. GLP-1 receptor agonists were associated with higher rates of treatment-emergent gastrointestinal adverse events but showed no significant differences in serious adverse events compared to placebo. FGF21 analogues, including efruxifermin studied in phase 2 trials, demonstrated efficacy in MASH resolution and fibrosis regression in patients with F2/F3 fibrosis, with the SYMMETRY Phase 2b trial achieving F4 regression within 96 weeks. These agents showed promise for accelerated approval pathways based on histologic reversal of cirrhosis, though long-term safety data continue to be collected in ongoing phase 3 studies.

Semaglutide's Evolving Role in the MASH Landscape

The treatment landscape for MASH has undergone significant transformation over the past five years, marked by the first FDA-approved therapies breaking through what was previously considered a "therapeutic graveyard." Two FDA-approved options now exist for noncirrhotic MASH with moderate-to-advanced fibrosis: resmetirom from Madrigal Pharmaceuticals and semaglutide. Resmetirom represents the first approved therapy specifically for MASH treatment, though questions regarding long-term efficacy, safety, durability, accessibility, and gastrointestinal adverse effects remain under investigation. This breakthrough followed years of failed pharmacotherapies, with the lack of approved treatments remaining an unsolved issue as recently as 2023 despite the increasing medical and socioeconomic burden of the disease.

Semaglutide has emerged as a particularly promising GLP-1 receptor agonist that improves liver histology in MASH through multiple mechanisms. Preclinical studies in two MASH models demonstrated that semaglutide improved histological markers of fibrosis and inflammation while reducing hepatic expression of fibrosis-related and inflammation-related gene pathways. Clinical trial data revealed 72 proteins significantly associated with MASH resolution and semaglutide treatment, most related to metabolism and several implicated in fibrosis and inflammation. An independent real-world cohort verified differential expression of these same proteins in MASH patients relative to healthy individuals, suggesting semaglutide may revert the circulating proteome associated with MASH toward the pattern observed in healthy populations, though long-term utility remains constrained by gastrointestinal intolerance and variable effects on hepatic outcomes.

The evolving therapeutic landscape now encompasses multiple mechanistic approaches under late-phase clinical evaluation, including incretin-based therapies, fibroblast growth factor-21 analogues, and combination strategies targeting bile acid pathways. Recent trial data from 2025-2026 demonstrate promising results across several drug classes: efimosfermin alfa showed acceptable safety profiles with predominantly mild-to-moderate gastrointestinal adverse events, empagliflozin significantly improved liver markers including ALT, AST, and FIB-4 scores alongside glycemic control, and saroglitazar demonstrated substantial reductions in liver stiffness measurements and controlled attenuation parameter values. The field is increasingly adopting a precision medicine paradigm that integrates pharmacologic and lifestyle interventions tailored to disease phenotype, genetic risk, and gut microbiome, while maintaining lifestyle intervention as the cornerstone of management with sustained weight loss targets of ≥5% for reducing hepatic steatosis, ≥7% for improving necroinflammation, and ≥10% for stabilizing or reversing fibrosis.

Semaglutide's Broadening Impact in MASH Treatment

Metabolic Dysfunction-associated Steatohepatitis (MASH) represents a significant and growing global health challenge, affecting millions and often progressing silently to advanced liver disease. Historically, treatment options have been limited, primarily relying on lifestyle interventions. However, the landscape is rapidly evolving, with pharmacological agents now emerging as pivotal tools in managing this complex condition.

Semaglutide, a well-established glucagon-like peptide-1 (GLP-1) receptor agonist, has already transformed the management of type 2 diabetes and obesity. Its recent conditional accelerated approval for MASH with significant or advanced liver fibrosis (F2/F3) marks a critical milestone. The new data from the ESSENCE Phase 3 program further solidifies semaglutide 2.4 mg's role, confirming its favorable hepatic safety and demonstrating benefits across diverse patient populations, including women in menopause and Japanese MASH patients. This broad applicability is crucial, given the heterogeneous nature of MASH and the need for inclusive treatment strategies.

Studies indicate that semaglutide significantly improves MASH resolution, reduces hepatic steatosis, and positively impacts metabolic parameters such as weight, glucose control, and lipid profiles. Beyond liver-specific benefits, it offers multi-organ protective effects, including reductions in cardiovascular risk and improvements in renal health, which are vital as MASH patients frequently succumb to extrahepatic complications. This comprehensive profile positions semaglutide as a strong candidate for first-line treatment, particularly for high-risk individuals with obesity or type 2 diabetes.

However, the evolving therapeutic landscape also presents considerations. While semaglutide excels in MASH resolution and metabolic improvements, research suggests its direct impact on fibrosis regression may be less pronounced compared to other emerging agents. Furthermore, common gastrointestinal adverse events, though generally mild to moderate, necessitate careful patient management to ensure adherence. Long-term data on preventing hard liver outcomes like cirrhosis and hepatocellular carcinoma also remain an area for continued investigation. As new therapies emerge, the focus will increasingly shift towards personalized, integrated care models, potentially involving combination strategies to address both hepatic and extrahepatic risks comprehensively, ensuring optimal outcomes for patients with MASH.